The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Teva Pharmaceutical

  • TEVA
  • NYSE
  • Consumer Products
  • Latest 55.18
  • Currency US$
  • Change 0.88
  • Percent Change 1.621 %
  • Volume 1,345,291
  • Tue Jul 22, 2014 01:12 PM EDT NYSE data delayed 15 minutes.
  • Open 54.46
  • Previous Close 54.30
  • High 55.33
  • Low 54.45
  • Bidx1 55.17
  • Askx4 55.19
  • 52-week High07/03 55.33
  • 52-week Low11/05 36.26
  • Beta 1.017
  • Market Cap 52,248.29M
  • EPS 5.11
  • P/E 10.798
  • Forward P/E 11.46
  • PEG 1.52
  • Annual Dividend 1.40
  • Yield 2.539

News

Financials & Calendars

Income Statement

  • Sales $20,414,000,000
  • Earnings $1,383,000,000
  • Return on Equity 6.06%

Cash Flow

  • Cash Flow --
  • Cash $901,000,000
  • Current Ratio 1.18

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $46,892,000,000
  • Liabilities $23,862,000,000
  • Liabilities-to-Equity Ratio 1.04

Price Ratios

  • Price to Sales 2.56
  • Price to Book 2.27
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings May 1 $1.23 Jul 31 $1.20
Surprises May 1 -0.81% n/a n/a
Dividends May 16 $0.35 n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 22, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.

Related Securities
Symbol Type Latest % Chg

Officers

  • Dr. Phillip Frost Chairman
  • Erez Vigodman President and Chief Executive
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

5 Basel Street P.O. Box 3190
PETACH TIKVA, L3
49131

Phone: (972)-3926-7267

kevin.mannix@tevapharm.com
www.tevapharm.com

Ideas & Discussion

Live Discussion of TEVA on StockTwits